Contact PR

To use this feature, join Babbler easily !


Babbler allows PR people and reporters to collaborate a better way.

By joining Babbler you will be able to access hundreds of newsrooms and PR contacts from your industrie(s) and also share with them your upcoming needs.

Their newsrooms are already on Babbler

You're 1 click away from signing up


Nice to see you again !

Press release

BRIGHT/LIGHTNING Sanofi Diabetes Update
timer minutes reading time minute reading time

Copy link
Background: For people with diabetes the early months of treatment with long-acting insulin are important for adherence and long-term outcomes

Click to get original image size

People with diabetes who experience low blood sugar events (hypoglycemia) during the first few months of treatment with basal insulin, tend to use more healthcare resources and are more likely to stop treatment than those who don’t.

Hypoglycemia can have a huge impact on people with diabetes and is associated with a high cost for healthcare systems and society. Fear of hypoglycemia by HCPs and patients can result in sub-optimal dosing, which can lead to serious long-term health complications.

Most dose adjustment is done, and most improvement in blood sugar control is achieved, in the early period of treatment, called the titration period. It is therefore important to ensure that people with diabetes requiring insulin get off to a “good start” and prevent lapses in treatment, or stopping it altogether.

Sanofi explored the benefit of Toujeo in Randomized Controlled Trials and Real World Evidence (RWE) to give a broad picture of how the treatment truly affects people with diabetes starting basal insulin therapy. 

Click the download button to read more.

  • Health & Medicine
  • Medicine
inscrit avec succès

Congratulations, you're registered on Babbler!

Discover now all the news waiting for you on Babbler: visit your newsfeed.!

Your topics have been selected, you can change it by clicking here

  • Health & Medicine
  • Medicine